

Supplementary Table 2. Mean number (SD) of ophthalmology visits and time intervals between visits for patients with CRVO or BRVO treated with ranibizumab injection or dexamethasone implant who had 24 months of follow-up data

	CRVO (<i>n</i> = 612)			BRVO (<i>n</i> = 800)		
	Ranibizumab injection (<i>n</i> = 539)	Dexamethasone implant (<i>n</i> = 73)	<i>P</i> -value	Ranibizumab injection (<i>n</i> = 713)	Dexamethasone implant (<i>n</i> = 87)	<i>P</i> -value
Number of visits						
All ophthalmology visits	11.0 (7.0)	9.3 (5.8)	0.115	10.5 (6.3)	9.0 (5.6)	0.038
Treatment visits	5.6 (4.5)	2.3 (1.9)	< 0.0001	5.0 (4.2)	2.2 (1.7)	< 0.0001
Non-treatment visits	5.3 (5.0)	7.0 (5.2)	0.006	5.5 (4.5)	6.8 (4.8)	0.030
Interval, days						
All ophthalmology visits	58.0 (46.5)	62.3 (33.6)	0.346	61.5 (41.8)	70.5 (49.4)	0.024
Treatment visits	70.7 (58.4)	174.2 (94.7)	< 0.0001	80.3 (78.8)	181.8 (95.5)	< 0.0001
Non-treatment visits	102.9 (82.9)	85.1 (64.8)	0.018	101.8 (71.0)	82.6 (46.1)	0.005

Data are shown as mean (SD).

BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; SD, standard deviation.